Skip to contentS
Skye Bioscience, Inc.
S
SKYESkye Bioscience, Inc. Released Mar 31, 2023, after the close
10-K filed Mar 31, 2023, 90 days after period end · 0001516551-23-000038
Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$9.89M-$9.89MderivedN/M vs Q4 2021 No earnings release is on file for this quarter. Its figures came with the 10-K.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Skye Bioscience, Inc. · CIK 1516551 · Engraved from SEC EDGAR
N/M vs Q3 2022
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$9,283,069N/M Operating Cash Flowderived-$4,871,522N/M Free Cash Flowderived-$4,884,026N/M ended Dec 31, 2022 · filed Mar 31, 2023 · 90 d after period end